Triptan nonresponder studies: implications for clinical practice.
about
EFNS guideline on the drug treatment of migraine - report of an EFNS task forceItalian guidelines for primary headaches: 2012 revised versionTreatment adherence among new triptan users: a 2-year cohort study in TaiwanWhy pharmacokinetic differences among oral triptans have little clinical importance: a comment.Clinical outcomes following supraorbital foraminotomy for treatment of frontal migraine headacheOptimizing the diagnosis and treatment of migraine.Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.Novel cutaneous uses for botulinum toxin type A.Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine.Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.Almotriptan: meeting today's needs in acute migraine treatment.A comparison of outcome of medical and surgical treatment of migraine headache: In 1 year follow-up.OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.Triptan nonresponders: do they exist and who are they?A review of needle-free sumatriptan injection for rapid control of migraine.Triptan use in Australia 1997-2015: A pharmacoepidemiological study.Effects of Pregabalin in Patients with Neuropathic Pain Previously Treated with Gabapentin: A Pooled Analysis of Parallel-Group, Randomized, Placebo-controlled Clinical Trials.MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan.Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine--satisfaction with treatment: reality with Almogran study.Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders.Patient preference for triptan formulations: a prospective study with zolmitriptan.Pharmacoepidemiology of triptans in a headache centre.Triptans: low utilization and high turnover in the general population.An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination.Effects of switching acute treatment on disability in migraine patients using triptans.Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine.OCT1 mediates hepatic uptake of sumatriptan and loss-of-functionOCT1polymorphisms affect sumatriptan pharmacokinetics
P2860
Q28219436-2E19EA2C-7CDB-4AE8-8756-A1A928303DF8Q30466790-03EA1EBF-DD0F-459C-BE23-4452CBBBC362Q34109369-0E02C1FF-F799-437A-9AD0-BAA609E0A52CQ34770884-96794497-5FBC-4B98-931D-21998E4318B4Q35861516-F04F7773-3013-4F48-A6EC-0130B8BBBB8BQ36207892-6D6A3566-3160-4D87-813A-B9ABB076ECE7Q36373560-30DF7301-1952-46AB-B828-0FEE2DAB597DQ36687429-79201E4B-D9DF-460B-80BC-9DCC0CD681EEQ36902009-DDAC9B05-A172-464B-811C-83EEFD2B2F79Q36947155-A6EFABD2-FF56-4030-A616-E12F7F4EBEB9Q37021307-F513E025-E1C3-45D1-85BC-2B5E293B0B89Q37157826-7DB4A0BA-2D57-4B61-BF2A-FCE0434CA574Q37650532-647BD6D4-5423-4D7C-98DF-A781C4EF3C82Q38096945-C2755781-05A0-42BD-9508-5FCDB34A1F0DQ38136254-88A7CCA9-C45D-4950-9C54-A92C5EA16FAAQ39017558-F84F00CC-94DF-44E4-A5FF-8CD1C2753CFCQ39167580-BC332013-2E09-426B-9B33-E5D6F00F1ACBQ39268172-0E108F64-E626-4523-B770-2E60A4B534CCQ39276728-3E89579A-13FB-4EB5-A90C-6EC497EF3EB3Q39348177-2D79EF0E-CD71-46A0-B524-93D40B402031Q39349941-8E4E4B63-B4FF-4F52-ADD9-8CBA19CFB2C1Q39355111-8234C216-8B73-4AA9-9578-5633B52C4F6FQ42632079-8C666BF1-9341-47C7-A3EA-6F4C3D5CE5BFQ42963774-891030A5-C266-4010-84F9-16F9BCBB55FCQ43280720-C3427F90-6FDB-42D1-B330-6AA2551F1324Q44175949-A436D741-93AC-4B65-A37E-F2A706ABC1A7Q45131483-4755D9DD-C37D-45EF-83BC-A400D84C5FFFQ45754964-A0DCF0D5-CF19-4153-BB24-B1E1EA40804CQ46442389-9257782E-9E2F-4C45-BCF9-641301F9DF24Q50350695-98DAAECA-9CFD-4F6B-9919-2DEA6941EF45Q54920214-49FEAC1E-0CEC-43D5-BA1F-B11238F657BCQ57988151-FB0D0918-F6C6-4422-935B-16DD30413FF2
P2860
Triptan nonresponder studies: implications for clinical practice.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Triptan nonresponder studies: implications for clinical practice.
@en
Triptan nonresponder studies: implications for clinical practice.
@nl
type
label
Triptan nonresponder studies: implications for clinical practice.
@en
Triptan nonresponder studies: implications for clinical practice.
@nl
prefLabel
Triptan nonresponder studies: implications for clinical practice.
@en
Triptan nonresponder studies: implications for clinical practice.
@nl
P1433
P1476
Triptan nonresponder studies: implications for clinical practice.
@en
P2860
P304
P356
10.1111/J.1526-4610.2005.05031.X
P577
2005-02-01T00:00:00Z